|
#ASCO22 poster abstract 10609 Building a multidisciplinary consortium in Iowa to advance genetic counseling and testing in patients with cancer Sandra Megally, Matthew Obinna Nwaneri, Joseph Kim, Limaya Atembina, Lorna Lucas, and Lu Anne Bankert Journal of Clinical Oncology 2022 40:16_suppl, 10609-10609 https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.10609?af=R  A multiphase continuing education and quality improvement initiative to tailor treatment plans for patients with follicular lymphoma.
https://meetings.asco.org/abstracts-presentations/206461 https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e18651 2022 ASCO Annual Meeting J Clin Oncol 40, 2022 (suppl 16; abstr e18651) DOI: 10.1200/JCO.2022.40.16_suppl.e18651 Authors Joseph Kim, Timothy S. Fenske, Linda Gracie-King, Marc David Viens, Victor Ocana, Abhinav Binod Chandra, David Penberthy, Tori McCurdy Organizations Q Synthesis LLC, Newtown, PA, Medical College of Wisconsin, Milwaukee, WI, Axis Medical Education, Fort Lauderdale, FL, AXIS Medical Education, Inc., Fort Lauderdale, FL, Yuma Regional Medical Center, Yuma, AZ, Bon Secours Mercy Health, Petersburg, VA, Baptist Cancer Center, Oakland, TN Psychosocial Challenges Experienced by Patients with SBS (Short Bowel Syndrome) https://www.akhcme.com/sbs-part1/ This continuing education activity is for psychiatrists, psychologists, and social workers who may be involved in the care of patients with SBS. ASCP, working in collaboration with Q Synthesis LLC, invites pathologists to participate in a unique cohort-based leadership development CME program called Pathology Trailblazers: HER2-low Breast Cancer Collaborative Learning Exchange.
This program will begin in May 2022 and run for approximately 3 months. Pathology Trailblazers: HER2-low Breast Cancer Collaborative Learning Exchange is designed to:
Learn more about this unique program here: https://www.ascp.org/content/learning/breast-cancer#trailblazers Join ASCP on Thursday March 10, 2022 at 8 pm Eastern for this CME Twitter Chat on the topic of HER2-low breast cancer. Instructions for this activity can be found here: https://www.ascp.org/content/learning/breast-cancer# Open Twitter at 8 pm Eastern Follow @ASCP on Twitter: https://twitter.com/ASCP_Chicago We encourage you to read this article for additional information about this topic: HER2-Low Breast Cancers: New Opportunities and Challenges.  This virtual tumor board from ASCP will help you understand the science and emerging evidence around HER2-low breast cancer, as well as changes to practice that will be necessary in preparation for anticipated approvals of HER2-low breast cancer therapies. Claim CME/CMLE credit at: https://store.ascp.org/productlisting/productdetail?productId=143142647
Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. This virtual tumor board from ASCP will help you understand the latest evidence regarding HER2-low breast cancer, HER2 testing guidelines, the implications for the pathology team as HER2-low therapies emerge, and ways to streamline communications with oncologists and other members of the cancer care team. Claim CME/CMLE credit at https://store.ascp.org/productlisting/productdetail?productId=143510393
Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. Improving the Quality of Care for Patients Harboring ALK+ NSCLC
CME activity here: https://reachmd.com/programs/cme/improving-quality-care-patients-harboring-alk-nsclc/12631/ This CME activity will review molecular testing for ALK rearrangements, approved and emerging therapeutic options for the first-line treatment of ALK+ NSCLC and treatment upon disease progression, treatment selection and sequencing, and efficacy and safety data of ALK inhibitors. HER2 In Breast Cancer: Testing Guidelines and New Treatment Approaches This CME/CMLE-accredited online course is designed to help Pathologists, laboratory professionals, and other members of the cancer care team apply the latest scientific evidence when evaluating HER2 status and be comfortable having an open dialogue surrounding challenging HER2 cases and how treatment is informed by HER2 status. Faculty also present information about how the emerging science around HER2‐low may impact patient care. Improving Quality of Care and Shared Decision-Making in Myelofibrosis
CME Activity: https://reachmd.com/programs/cme/part-1-improving-quality-care-and-shared-decision-making-myelofibrosis/11997/ This activity will review recent advances and critical concepts that affect outcomes, including symptom burden, molecular diagnostics, prognostic risk stratification scores, and the treatment and management of MF. |
